Orphagen Pharmaceuticals announced today that the National Cancer Institute (NCI) has awarded a Phase I SBIR grant to the Company for development of a new class of small molecule drugs for the treatment of adrenocortical and prostate cancer. The objective of the...

Orphagen Pharmaceuticals announced today that it has been awarded a two year federal grant to further characterize a novel class of small molecule drugs with potential to treat circadian rhythm sleep disorders and more serious psychiatric illnesses, such as anxiety,...

Orphagen Pharmaceuticals, Inc., a privately held company (“Orphagen”) today announced that it has entered into a Collaboration and License Agreement with Japan Tobacco Inc., (“JT”) to discover, develop and commercialize drugs in the areas of immunology and...